Explore KDIGO 2025 IgA nephropathy shifts: treat earlier at proteinuria >0.5 g/day, dual-pathway therapy aims to preserve GFR. Welcome back to another AJMC Insights series. In this episode titled, ...

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...

Please provide your email address to receive an email when new articles are posted on . Remission of proteinuria to less than 0.3 g per day was linked to greater eGFR preservation for patients with ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN) ...

LONG BEACH, Calif. -- Iptacopan (Fabhalta) was safe and effective for reducing proteinuria in biopsy-confirmed immunoglobulin A nephropathy (IgAN), according to interim findings from the phase III ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with iptacopan had a 38.3% reduction in proteinuria at 9 months. Iptacopan was well-tolerated ...

Using human-induced pluripotent stem cell-derived kidney organoids, researchers from Science Tokyo uncovered how abnormal Hippo signaling drives fibrosis in nephronophthisis, a genetic kidney disorder ...

About 13% of African Americans carry two copies of the APOL1 gene variants linked to kidney disease, yet most will never know ...

Dimerix Ltd (ASX:DXB, OTC:SBMJF) has moved to strengthen the clinical and regulatory footing of its lead kidney disease program, confirming its pivotal ACTION3 trial remains on track with a high ...